Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$761 Mln
Revenue (TTM)
$11 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.5
Industry P/E
--
EV/EBITDA
-0.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.2
Face value
--
Shares outstanding
87,012,304
CFO
$-83.62 Mln
EBITDA
$-198.19 Mln
Net Profit
$-204.30 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immunome Inc (IMNM)
| -14.5 | 6.9 | 11.0 | -27.0 | 46.0 | -- | -- |
|
BSE Sensex
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Immunome Inc (IMNM)
| -0.7 | 384.2 | -82.9 | 33.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immunome Inc (IMNM)
|
9.1 | 761.4 | 10.9 | -205.1 | -1,625.0 | -78.6 | -- | 2.5 |
| 49.8 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.2 | 8,290.2 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.2 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.2 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 44.9 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 53.9 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 313.5 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 4.9 |
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and... IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Address: 18702 North Creek Parkway, Bothell, WA, United States, 98011 Read more
President, CEO & Chairman
Dr. Clay B. Siegall Ph.D.
President, CEO & Chairman
Dr. Clay B. Siegall Ph.D.
Headquarters
Bothell, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Immunome Inc (IMNM) stood at $ 373 Mln as on 31-Mar-25
The share price of Immunome Inc (IMNM) is $9.08 (NASDAQ) as of 24-Jun-2025 12:39 EDT. Immunome Inc (IMNM) has given a return of 45.96% in the last 3 years.
Immunome Inc (IMNM) has a market capitalisation of $ 761 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Immunome Inc (IMNM) is 2.47 times as on 23-Jun-2025, a 11% discount to its peers’ median range of 2.79 times.
Since, TTM earnings of Immunome Inc (IMNM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immunome Inc (IMNM) and enter the required number of quantities and click on buy to purchase the shares of Immunome Inc (IMNM).
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Address: 18702 North Creek Parkway, Bothell, WA, United States, 98011
The CEO & director of Dr. Clay B. Siegall Ph.D.. is Immunome Inc (IMNM), and CFO & Sr. VP is Dr. Clay B. Siegall Ph.D..
There is no promoter pledging in Immunome Inc (IMNM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Immunome Inc (IMNM) | Ratios |
|---|---|
|
Return on equity(%)
|
-78.58
|
|
Operating margin(%)
|
-1625.04
|
|
Net Margin(%)
|
-1875.21
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Immunome Inc (IMNM) was $0 Mln.
$0.34
(
